기타경영사항(자율공시) (HLB 간암 1차 치료제(리보세라닙,캄렐리주맙 병용요법)FDA로부터 보완요구서한(CRL,Complete Response Letter)수령)[코]
Received: 7/10/2026 · Reporter: HLB
HLB는 간암 1차 치료제 개발과 관련해 FDA로부터 보완요구서(CRL)를 받았습니다.
🏢 Past 12 months filing pattern (this company)
- Total filings
- 50 filings
- Same category
- 30 filings
- Previous same-category filing
- 9/8/2026
- Corrections / withdrawals
- 0 filings
Filing source / License
The original PDF/HTML of this filing is provided by FSS DART. MarketBubbles displays only metadata (title, receipt number, type, reporter) and a rule-based summary; we do not mirror the original PDF body (per FSS ToS).